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Pre-clinical studies suggest that 16:4(n-3) in purified form or as a component of fish oil might induce 
platinum-based chemotherapy resistance. Our aim was to determine plasma total and free 16:4(n-3) 
before and during platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients 
supplemented with fish oil or provided standard care, and to explore relationships between plasma 
16:4(n-3) levels and tumor response to treatment. 
Methods:  
In a retrospective, secondary data analysis of a prior clinical trial, plasma from patients with NSCLC 
(n = 21) who underwent platinum-based chemotherapy and were assigned to 2.2 g/day of 
eicosapentaenoic (EPA) plus 1.1 g DHA/day as fish oil (FO; n = 12) or received no intervention 
(standard care; SC; n = 9). Plasma 16:4(n-3) was quantified as free and esterified (total) fatty acid 
using HPLC-MS/MS. Plasma 16:4(n-3) levels were evaluated over time in relation to fish oil 
supplementation and response to platinum-based therapy.   
Results:  
Plasma 16:4(n-3) was detected in all samples. The percentage change/day in plasma esterified (total) 
16:4(n-3) was higher for FO versus SC group (2.7 versus -1.8%/d, U = 20,  p= .02), but change in 
plasma free 16:4(n-3) was not different between FO and SC. Median plasma free and esterified 
16:4(n-3) were similar between responders and non-responders to platinum-based chemotherapy. 
Total and free plasma 16:4(n-3) fatty acids were similar between NSCLC patients and REF (NSCLC 
vs REF: total 16:4(n-3): 122.9 vs. 95.2 nM and free 16:4(n-3) 23.9 vs. 27.6 nM).  
Conclusions:   
This first of its kind study that evaluated plasma 16:4(n-3) in NSCLC patients showed that 16:4 (n-3) 








The question of whether or not to consume fish and their oils during chemotherapy treatment for 
cancer is of interest to oncologists as well as patients and their families. The majority of evidence 
derived from experimental models of cancer treatment as well as human studies, suggests that 
provision of fish oil, as a source of the long chain EPA and DHA, concurrent with chemotherapy 
treatments, attenuates inflammation and improves the tumor effectiveness of anti-neoplastic drugs 
without imposing additional toxicity on the host (1–3). Ongoing discussions on controversial findings 
from a series of studies by a single research group (4–7) recently implicated the n-3 fatty acid 
hexadeca-4,7,10,13-tetraenoic acid [16:4(n-3)] in the development of chemoresistance. In tumor-
bearing mice, circulating mesenchymal stem cells (MSCs) injected either at the site of or distant to the 
tumor were recruited to the tumor site (4). Platinum chemotherapy (cisplatin) stimulated MSCs to 
secrete the n-3 fatty acid, 16:4(n-3), determined to be responsible for inducing resistance to a number 
of anti-neoplastic agents (4). MSCs, as well as 16:4n-3 production might be activated by platinum-
based chemotherapy. In tumor-bearing mice, 2.5 pmol of purified 16:4(n-3) orally administered 
induced chemotherapy resistance; cisplatin did not shrink tumors and tumor size was not different 
from those of a control group receiving vehicle alone. These findings when tested in experimental 
models by other groups remain uncorroborated and hence are the only line of research to question the 
use of 16:4n-3 in experimental models of cancer.     
Commercially available fish oils may be a source of 16:4(n-3) in addition to providing the precursor 
for endogenous synthesis of 16:4(n-3)(5). In a series of follow-up experiments, Daenen et al (5) 
detected 16:4(n-3) in unspecified commercially available fish oil supplements to reveal a range of 
16:4(n-3) concentrations from 0.2 to 5.7 μM. In healthy humans, consumption of both 10 and 50 ml of 
these fish oils, resulted in detection of plasma 16:4(n-3) during the postprandial period (8 hours), 
which was higher than that following oral intake of oily fish (5).  As little as 1 μL of fish oil 
[containing 5.4 μM 16:4(n-3)] induced chemotherapy resistance at the same level as purified 16:4n-3 
in BALC/c mice bearing the C26 colon carcinoma.   
The controversy that stemmed from the publication of a series of work from Daenen et al. was fueled 
in part by the lack of recognition of the studies that had reported improved response of tumors to a 
variety of chemotherapy treatments including  platinum-containing therapies during supplementation 
with n-3 fatty acids such as those found in fish oil. Since the time of the publication, there have been 
even more studies that have evaluated a variety of drug and tumor combinations in both human and 
preclinical experimental models, to show that fish oils are safe,  and often beneficial to the host while 
enhancing drug efficacy to the tumor (2).  Therefore, results of this experimental series are not aligned 
with the context of other work in this area and the importance of 16:4n-3 in humans is not yet 
resolved (8,9), thereby prompting the current study. This retrospective analysis uses a prospectively 




(NSCLC) undergoing platinum-based chemotherapy.  Patients were assigned to fish oil supplements 
or standard of care to answer questions related to safety of fish oil supplementation during cisplatin 
treatment and to determine its relevance to chemoresistance in humans with cancer.  The objectives 
were to:  determine plasma levels of 16:4(n-3) before and during administration of platinum-based 
therapy; explore whether plasma 16:4(n-3) concentrations increase with intake of fish oil 
supplements; and explore potential relationships between plasma 16:4(n-3) concentrations and 
response to chemotherapy. 
 
Materials and Methods 
Study design 
Plasma samples from NSCLC patients were available from the ‘Murphy trial’ (10,11) for which 
patients were accrued at the Cross Cancer Institute (Edmonton, Canada) between 2007 to 2009 for 
evaluating the effects of non-randomized intervention of fish oil supplementation compared to 
standard care during platinum-based chemotherapy (cisplatin and/or carboplatin doublet therapy) in 
NSCLC patients. The Murphy trial (10,11) enrolled 40 NSCLC patients who underwent at least 6 
weeks of first line platinum-based doublet chemotherapy. Patients opted to receive either standard 
care (SC) or fish oil (FO) in an open label study design. Based on previous phase I and II studies of 
Fearon, Barber and Wigmore (12,13), fish oil supplementation was dosed to meet 2.2 g EPA/day plus 
1.1 g DHA/day as either 7.5 ml liquid FO or 4 x 1g capsules of FO per day depending on patient 
preference to achieve the desired dose.  The fish oil dose was determined from the literature and 
supported a minimum effective dose of 2.0 grams of EPA in attenuating muscle loss in cancer 
cachexia (12). Compliance was reported to be at least 90% across the FO group as determined by 
capsule/liquid counts, patient records, and an increase in plasma EPA and DHA concentrations. 
Baseline characteristics of these groups were compared to a standard care group of patients with the 
same diagnosis and treatment plan to confirm lack of bias in the patient allocation in each arm of this 
open label study. Outcomes included muscle mass and tumor response to therapy (defined as 
complete response, partial response, or stable disease from CT scans of tumor and/or metastases). 
Plasma was collected from each group at the time of diagnosis (baseline) and one day before each of 
four cycles of chemotherapy coinciding with blood draws as part of standard clinical care and stored 
at -80°C until analysis. Written consent to use samples banked from the Murphy Trial was obtained 
during enrollment. This study was approved by the Health Research Ethics Committee of Alberta 
(ETH23340 and ETH24078). Plasma from a reference group of non-cancer controls (REF) was 
obtained from 11 adult men [median age 57y (47-68y)] participating in a study assessing responses 






From the remaining stored plasma samples, patients who provided both a baseline blood sample and 
at least one sample during 2-4 cycles (approximately 6-12 weeks) of platinum-based chemotherapy 
were selected for analysis of 16:4(n-3), EPA and DHA content.  
Plasma samples were matched to data on patient characteristics and treatment protocols were 
collected (10,11). Treatment response was collected retrospectively from medical records. Treatment 
response was determined by oncologists through physical exam accompanied by CT imaging.   
 
Fatty acid analysis 
Analysis of plasma EPA and DHA in plasma were quantified in plasma phospholipids (PL) as 
described earlier (10) and expressed as the total amount (μg/ml) and proportion (% w/w, ‘free’) of 
total fatty acids. Briefly, the Folch method was used to extract plasma lipids and phospholipids were 
isolated using G plates. Bands corresponding to the PL band were scraped and directly methylated 
prior to analyzing fatty acid methyl esters (FAME) using gas liquid chromatography.  
Protocols for quantifying free and total 16:4(n-3) levels in human plasma were established based on 
the methods from Bollinger (15). Plasma levels of 16:4(n-3) were evaluated using derivatization 
coupled with LC-MS/MS.  Validation methods and results of fatty acid analysis are outlined in the 
supplementary material.       
      
To determine free 16:4(n-3) concentration, plasma (80 µl) was added to glass tubes and an internal 
standard (final concentration 25 nM) was added; volume was adjusted to 125 µl with water (HPLC 
grade). Methanol (250 µL) was added and tubes were gently mixed prior to adjusting the pH < 2 with 
1M HCl. Isooctane (750 µl) was added and the mixture was gently vortexed for 2 minutes. Tubes 
were centrifuged at 1500 g for 2 minutes at room temperature (RT). The upper organic phase was 
collected, and the mixture re-extracted with another 750 µL of isooctane. Tubes were then centrifuged 
at 1500 g for 2 minutes at RT and the upper phase added to the previous extract. Extracts were 
evaporated under nitrogen. Dried extracts were derivatized using a commercially available AMP+ 
Derivatization kit (Cayman Chemicals). To the dried extract, 20 µL of cold 4:1 Acetonitrile/DMF, 20 
µL of cold EDC solution, 10 µL of HOBt solution and 30 µL of the AMP+ solution was added, then 
vortexed and heated (30 minutes, 60 °C). After cooling, the sample was immediately stored at -30 °C 
until analysis.  
      
To determine total 16:4(n-3) concentration in plasma, 10 µL methanol and 12.5 µL NaOH were added 
to 10 µL plasma and mixed. The mixture was heated to 60 °C on a heating block for 30 minutes. The 




volume adjusted to 125 µL with water. To the tubes, 250 µL methanol and 750 µL isooctane were 
added and extracted and derivatized as described for free 16:4(n-3) determination. 
      
LC-MS/MS analysis was performed on an Agilent 1260 Infinity system coupled to an AB Sciex 3200 
QTRAP®. Fatty acid separation was performed on a Phenomenex Luna Omega C18 column (50 x 
2.1mm, 1.6 µm) with a SecurityGuard ULTRA C18 guard column. Column oven and autosampler 
temperatures were set at 40 °C and 10 °C, respectively. Mobile phase A was 0.1% formic acid in 
water and mobile phase B was 0.1% formic acid in acetonitrile. The gradient was 15.5 minutes and 
was performed as follows: 30-70% B in 8 minutes, increased to 100% B in 0.5 min and held at 100% 
B for 2 minutes, then 30% B in 0.5 minute and equilibrated at 30% B for 4.5 min. The flowrate was 
0.5 mL/min and the injection volume was 5 µL. The mass spectrometer was operated in positive mode 
using multiple reaction monitoring scans. 
      
Data Analysis 
Since 16:4(n-3) values were not normally distributed, data was analyzed using non-parametric tests. 
Descriptive statistics were presented as median (range) for continuous data or count (%) for 
categorical data, stratified for treatment group. For categorical data, between-group differences were 
explored using Fisher’s exact test. To test for correlations between plasma fatty acids, we used 
Spearman’s Rho, and changes in fatty acid concentrations from pre- to post-chemotherapy 
administration were evaluated within group change using the Sign test. Change rates (i.e., % change 
per day to account for differences in timing between the samples) were assessed using the total 
change in 16:4(n-3) between two blood draws divided by the number of days between blood draws 
and compared between groups using the Mann-Whitney U test. Treatment response was collapsed 
into ‘response’ (complete response, partial response, stable disease) and ‘no response’ (progressive 
disease) categories. Differences in follow-up 16:4(n-3) concentrations between ‘response’ and ‘no 
response’ categories were tested using Mann Whitney U test. 
 
Results 
Of the 40 patients in the Murphy trial (10,11), 23 patients at baseline (FO = 12, SC = 11) and 21 
patients during chemotherapy (FO = 12, SC = 9) had sufficient plasma samples available for 
additional fatty acid analyses of 16:4 (n-3). There were no significant differences in baseline 





Plasma 16:4(n-3) levels and fish oil supplementation 
The fatty acid 16:4(n-3) was detected in both the free and esterified (total) fractions in all patient and 
reference samples. In the FO group, total 16:4(n-3) significantly increased from baseline to follow-up 
(p = 0.007; Table 2). In the SC group, total 16:4(n-3), free 16:4(n-3), EPA and DHA did not change 
during chemotherapy. Compared to baseline, FO supplementation was associated with a greater 
increase in total plasma 16:4(n-3) and plasma EPA when compared with the SC groups (p = 0.02 and 
p = 0.02) (Table 2).  To account for differences in the number of days between blood draws, a 
%change/day was calculated.  Plasma total 16:4(n-3) was higher for FO versus SC group (2.65%/d 
versus -1.81%/d, U = 20, p = 0.02), but change/day in plasma free 16:4(n-3) was not different 
between FO and SC. There was a strong, positive correlation between the amount of plasma EPA and 
both total 16:4(n-3) (rs = 0.76, p < 0.001) and free 16:4(n-3) rs = 0.696, p < 0.001). There was a 
moderate positive correlation between DHA and total, but not free 16:4(n-3) (rs = 0.478, p = 0.03). 
 
Plasma 16:4(n-3) levels and treatment response 
Of the patients who received chemotherapy (n = 21), seven had progressive disease and 14 responded 
to treatment [stable disease (n = 8), partial response (n = 3), and complete response (n = 3)]. There 
was no significant difference in median total plasma 16:4(n-3) in those who responded to treatment 
versus those with progressive disease (respectively 109.5 (64.1-476.3) versus 94.9 nM (36.1-663.8), p 
= 0.37) or the free plasma fatty acid fraction (respectively 22.4 (2.4-160) versus 23.6 nM (3.9-74.6), p 
= 0.88) (Figures 1 & 2). 
 
Plasma 16:4(n-3) levels in cancer versus non-cancer controls 
To explore the expected range of 16:4(n-3) in plasma of people without cancer, we evaluated plasma 
free and total 16:4(n-3) in free living participants. There was no significant difference between pooled 
baseline NSCLC patients (FO + SC) versus REF subjects: median plasma total 16:4(n-3) [122.93 
(37.2-567.4) versus 95.21 nM (40.5-214.1), respectively (p = 0.73)] or free 16:4(n-3) [26.18 (4.5-93) 
versus 27.57 nM (17.5-86.2), respectively (p = 0.47)]. 
 
Discussion 
The most important finding of this study is that plasma 16:4(n-3) does not affect the tumor response to 
platinum-based therapies in humans. The data aligns with many human and experimental studies but 
contrasts with a series of preclinical studies that implied fish oil supplementation and consumption of 
oily fish could be harmful when taken concurrently with platinum-based chemotherapy. To our 
knowledge, this is the only available biological dataset with the patient group, supplementation, and 




treatment for cancer in humans. Although this study was limited to NSCLC and did not investigate the 
full spectrum of platinum-based chemotherapies, cisplatin, and carboplatin are two widely used 
chemotherapy drugs in standard care, including in countries where fish is often consumed.  The data 
do not support the notion that 16:4(n-3) levels associate with a reduced treatment response. 
The most recent publication by Daenen et al. concluded that “The use of [fish oil] products 
during chemotherapy treatment should be avoided,” which gathered considerable media attention and 
subsequently it was recommended that “Fish oil and fish containing high levels of 16:4(n-3) [one of 
the fatty acids mentioned before] may best be avoided on days surrounding chemotherapy” (5). This 
recommendation collides with current health policies, clinical practice guidelines as well as daily 
clinical oncological practice. Notably, dietary recommendations are made by National health agencies 
(such as the Food and Drug Administration in the United States) based on best available evidence as 
well as information on minimum required amounts of essential nutrients and upper limit of safety to 
set standards and regulations using specific standards of evidence. While there are currently no formal 
recommendations for fish oil there are recommendations for intake of omega-3 fatty acids, for alpha-
linolenic acid (18:3n-3), and for EPA+DHA among the healthy population in some countries and 
regions.  In the oncology setting, the European Society of Parenteral and Enteral Nutrition (ESPEN, 
2017) is the leading agency that sets nutritional guidelines based on best available evidence and 
recommends use of n-3 PUFA, in the form of fish oils, for advanced cancer patients undergoing 
chemotherapy who are at risk of weight loss or muscle wasting (16).     
Our data indicate that 16:4(n-3) is present in total and, to a lesser amount, free fatty acid fractions of 
plasma, before chemotherapy has commenced at a level similar to that observed in a reference group 
of non-cancer controls. Levels of plasma total 16:4(n-3) detected in all groups were variable and 
higher than previously reported in healthy volunteers (5). Total fatty acids represent the collection of 
fatty acids in the lipoproteins including phospholipid, triglyceride, and cholesterol esters. Lipoproteins 
are derived from the liver and intestine during the postprandial period. Therefore, the presence of 
16:4(n-3) at baseline and in the reference group suggests that 16:4(n-3) is present naturally in those 
consuming North American diets. Majority of plasma free fatty acids are derived from stored lipids in 
peripheral tissue and our results suggest storage of 16:4n-3 in adipose tissue. As anticipated, plasma 
total 16:4(n-3) positively correlated with EPA and increased after fish oil supplementation, a result 
consistent with Deanen et al. who reported elevated plasma total 16:4(n-3) levels for at least 8 hours 
following ingestion of a fish oil supplement in healthy humans (n=30) (5). Unlike the experimental 
series of Roodhardt et al, we did not detect a plasma free or total 16:4(n-3) response following 
platinum therapy in NSCLC patients. This may relate to timing of measurement in our study; subjects 
were on daily fish oil supplement which could have been consumed at any time within the 24 hours 
around their chemotherapy infusion.  Blood samples analyzed for 16:4(n-3) levels were drawn just 




institution (for example to assess hematological toxicities from chemotherapy). Therefore, whether 
the concentration of 16:4n-3 would relate to timing of cisplatin delivery cannot be established by the 
current study and this is recognized as a limitation given the retrospective nature of the analysis. 
Although this resulted in variable follow-up time points, we standardized baseline and follow-up 
differences by testing for change over time. Further, we had access to a small reference group of non-
cancer subjects that were collected during the same time period for comparison.  We also 
acknowledge the small sample size. In spite of these limitations, we were able to address the question 
of whether 16:4n-3 relates to tumor response which is revealed with the current study design.  We 
also aimed to correct for number of days on chemotherapy and fish oil by standardizing to a daily 
unit.  An important note is that the sensitivity of detection of 16:4(n-3) is greater than that used in the 
experimental series of Daenen et al.  
Given the recognized importance of consuming fish and their oils in our diet as a source of 
essential n-3 fatty acids, and potential benefits of fish oil supplementation during chemotherapy, our 
data provides additional evidence supporting ESPEN guidelines, which actively recommends the 
consumption of fish oil during cancer treatment. An adequate intake (AI) of omega-3 fatty acids in 
humans is 1.1 g for females and 1.6 g for males based on best evidence from human studies (17). 
Platinum-based chemotherapy treatment did not influence plasma 16:4(n-3). While fish oil 
supplementation increases the amount of 16:4(n-3) in plasma, this fatty acid was not associated with 
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Table 1 Participant characteristics at baseline 
      
      REF (n=11) NSCLC FO (n=12) NSCLC SC (n=11) 
Age, median (range), 
years 
57 (47-68) 63 (45-72) 67 (57-76) 
Sex, No. (%)           
  Male 11 (100) 8 (67) 5 (46) 
  Female 0 4 (33) 6 (54) 



























REF, Reference group of non-cancer controls; NSCLC, non-small cell lung cancer; FO, fish oil group; 
SC, standard care group 






Table 2. Within group differences of plasma PUFAs during platinum-based chemotherapy treatment 
 REF (n=11) NSCLC FO (n=12) NSCLC SC (n=11) 




















































REF, Reference group of non-cancer controls; NSCLC, non-small cell lung cancer; FO, fish oil group; 
SC, standard care group; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid. 
aSign test (exact significance, 2-tailed) using binomial distribution comparing absolute median values 
at baseline and follow-up within each group where *p<0.05, **p<0.001 






Figure 1. Follow-up total 16:4(n-3) by treatment response in non-small cell lung cancer patients. 
Figure 2. Follow-up free 16:4(n-3) by treatment response in non-small cell lung cancer patients.  
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6 hr on a benchtop at room temperature
Sample Name Actual Conc. (nM) Value #1 Value #2 Value #3 Mean Std. Dev. Percent CV Accuracy (%)
Plasma Blank 16.76 17.26 17.14 16.55 16.98 0.38 2.23 101.35
QC Low 24.75 25.71 24.19 24.65 24.85 0.78 3.14 100.38
QC Mid 36.75 35.27 34.95 36.45 35.56 0.79 2.22 96.76
QC High 96.73 104.73 98.33 97.46 100.17 3.97 3.96 103.56
30 days stored at -30 °C (Freezer)
Sample Name Actual Conc. (nM) Value #1 Value #2 Value #3 Mean Std. Dev. Percent CV Accuracy
Plasma Blank 16.76 15.11 15.63 16.32 15.69 0.61 3.88 93.61
QC Low 24.75 25.13 24.30 25.16 24.86 0.49 1.97 100.44
QC Mid 36.75 35.10 35.31 34.50 34.97 0.42 1.20 95.16




Plasma levels of Platinum-Induced Fatty Acid [16:4n-3] do not affect response to platinum-based 
chemotherapy: a pilot study in non-small cell lung cancer patients 




Fatty Acid Validation 
Methods 
The analytical method used in the quantification of fatty acid in human plasma was validated for 
selectivity, carryover, extraction recovery, matrix effect, linearity, accuracy and precision, and stability. 
 
Selectivity 
Specificity was evaluated according to the following: 80 µL water (done in triplicate) was saponified, 
extracted and derivatized according to the methods outlined and were analyzed for interferences at the 
retention times of the analyte and internal standard. 
 
Accuracy and Precision 
Accuracy and precision were determined by extracting plasma spiked at three concentrations on three 
separate days. QC samples spiked at 8, 20 and 80 nM were extracted and analyzed in triplicate. Precision 
was assessed by calculating the coefficient of variation and accuracy was calculated using the following 
equation below. Precision should be less than 15% and accuracy should be in the range of 85-115%. 
Accuracy (%) = Final concentration calculated
(Endogenous concentration+ Spiked concentration)
 x 100 
 
Stability 
Stability was investigated by extracting and analyzing triplates of QC samples (spiked concentrations 8, 
20, 80 mM) at the following conditions: 1) autosampler condition (10 °C) for 6 and 12 hours; 2) benchtop 
 
 
for 6 hours; 3) four freeze/thaw cycles; and 4) storage at -30 °C for 30 days. The results were calculated 




There were no interferences observed at the retention times of FA(16:4n-3) and its internal standard. The 















































Accuracy and Precision 
The following tables summarize the accuracy and precision for the QC samples (n=3). Each day is listed 
individually and the replicates, mean, standard deviation, precision (%CV) and accuracy are shown. The 




The following tables summarize the results of the stability assessments. The accuracy of the QC samples 
were all in the acceptable range (85-115%), which is an indication that there was no significant 
degradation of the analyte under the conditions tested. 
 
 
